These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 6403716)

  • 1. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial.
    Zincke H; Utz DC; Taylor WF; Myers RP; Leary FJ
    J Urol; 1983 Mar; 129(3):505-9. PubMed ID: 6403716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group.
    Bouffioux C; Denis L; Oosterlinck W; Viggiano G; Vergison B; Keuppens F; De Pauw M; Sylvester R; Cheuvart B
    J Urol; 1992 Aug; 148(2 Pt 1):297-301. PubMed ID: 1635122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H; Benson RC; Hilton JF; Taylor WF
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does intravesical chemotherapy prevent invasive bladder cancer?
    Green DF; Robinson MR; Glashan R; Newling D; Dalesio O; Smith PH
    J Urol; 1984 Jan; 131(1):33-5. PubMed ID: 6418897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder.
    Pan JS; Slocum HK; Rustum YM; Greco WR; Gaeta JF; Huben RP
    J Urol; 1989 Dec; 142(6):1589-93. PubMed ID: 2511340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone.
    Kurth KH; Schröder FH; Tunn U; Ay R; Pavone-Macaluso M; Debruyne F; de Pauw M; Dalesio O; ten Kate F
    J Urol; 1984 Aug; 132(2):258-62. PubMed ID: 6376827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer.
    Br J Urol; 1985 Dec; 57(6):680-5. PubMed ID: 2867800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
    Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of superficial bladder tumors in a controlled trial with thio-TEPA versus adriamycin.
    Horn Y; Eidelman A; Walach N; Yuval E; Markowitz A
    J Surg Oncol; 1984 Sep; 27(1):67-9. PubMed ID: 6434883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS; Jordan AM; Murphy WM
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preliminary results of a randomized study between intravesical adriamycin and thio-tepa in the treatment of superficial tumors of bladder].
    Allona Moncada A; Santos García Vaquero I; Polo Villar G; Díaz González R; González Martín M; Zuloaga Gómez A; Martínez Torres JL; Rodríguez Alvarez J; Duarte Vázquez JJ; Megino López JF
    Arch Esp Urol; 1984; 37(2):113-22. PubMed ID: 6431914
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group.
    Kurth KH; Bouffioux C; Sylvester R; van der Meijden AP; Oosterlinck W; Brausi M
    Eur Urol; 2000; 37 Suppl 3():1-9. PubMed ID: 10828681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma.
    Garnick MB; Schade D; Israel M; Maxwell B; Richie JP
    J Urol; 1984 Jan; 131(1):43-6. PubMed ID: 6690745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
    Tanimoto R; Saika T; Ebara S; Kobayashi Y; Nasu R; Yamada D; Takamoto H; Miyaji Y; Nasu Y; Tsushima T; Kumon H
    World J Urol; 2018 Jun; 36(6):889-895. PubMed ID: 29387931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy in different risk-groups of patients with superficial bladder cancer.
    Startsev V; Pouline I
    Arch Ital Urol Androl; 2005 Jun; 77(2):93-8. PubMed ID: 16146269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.